> top > docs > PubMed:32616067 > annotations

PubMed:32616067 JSONTXT

Annnotations TAB JSON ListView MergeView

LitCovid-PD-FMA-UBERON

Id Subject Object Predicate Lexical cue fma_id
T1 689-692 Body_part denotes arm http://purl.org/sig/ont/fma/fma24890
T2 924-927 Body_part denotes arm http://purl.org/sig/ont/fma/fma24890
T3 982-985 Body_part denotes arm http://purl.org/sig/ont/fma/fma24890
T4 1052-1055 Body_part denotes arm http://purl.org/sig/ont/fma/fma24890
T5 1324-1329 Body_part denotes blood http://purl.org/sig/ont/fma/fma9670
T6 1396-1401 Body_part denotes serum http://purl.org/sig/ont/fma/fma63083
T7 1441-1444 Body_part denotes arm http://purl.org/sig/ont/fma/fma24890
T8 1489-1492 Body_part denotes arm http://purl.org/sig/ont/fma/fma24890
T9 2489-2495 Body_part denotes kidney http://purl.org/sig/ont/fma/fma7203
T10 2552-2557 Body_part denotes heart http://purl.org/sig/ont/fma/fma7088
T11 2610-2615 Body_part denotes liver http://purl.org/sig/ont/fma/fma7197
T12 2668-2675 Body_part denotes glucose http://purl.org/sig/ont/fma/fma82743
T13 4037-4040 Body_part denotes Arm http://purl.org/sig/ont/fma/fma24890
T14 4577-4580 Body_part denotes Arm http://purl.org/sig/ont/fma/fma24890
T15 5106-5109 Body_part denotes Arm http://purl.org/sig/ont/fma/fma24890

LitCovid-PD-UBERON

Id Subject Object Predicate Lexical cue uberon_id
T1 689-692 Body_part denotes arm http://purl.obolibrary.org/obo/UBERON_0001460
T2 924-927 Body_part denotes arm http://purl.obolibrary.org/obo/UBERON_0001460
T3 982-985 Body_part denotes arm http://purl.obolibrary.org/obo/UBERON_0001460
T4 1052-1055 Body_part denotes arm http://purl.obolibrary.org/obo/UBERON_0001460
T5 1324-1329 Body_part denotes blood http://purl.obolibrary.org/obo/UBERON_0000178
T6 1396-1401 Body_part denotes serum http://purl.obolibrary.org/obo/UBERON_0001977
T7 1441-1444 Body_part denotes arm http://purl.obolibrary.org/obo/UBERON_0001460
T8 1489-1492 Body_part denotes arm http://purl.obolibrary.org/obo/UBERON_0001460
T9 2489-2495 Body_part denotes kidney http://purl.obolibrary.org/obo/UBERON_0002113
T10 2552-2557 Body_part denotes heart http://purl.obolibrary.org/obo/UBERON_0000948
T11 2610-2615 Body_part denotes liver http://purl.obolibrary.org/obo/UBERON_0002107

LitCovid-PD-MONDO

Id Subject Object Predicate Lexical cue mondo_id
T1 54-72 Disease denotes infeCtious disease http://purl.obolibrary.org/obo/MONDO_0005550
T2 104-113 Disease denotes infection http://purl.obolibrary.org/obo/MONDO_0005550
T3 361-385 Disease denotes coronavirus disease 2019 http://purl.obolibrary.org/obo/MONDO_0100096
T4 387-395 Disease denotes COVID-19 http://purl.obolibrary.org/obo/MONDO_0100096
T5 577-585 Disease denotes COVID-19 http://purl.obolibrary.org/obo/MONDO_0100096
T6 655-663 Disease denotes COVID-19 http://purl.obolibrary.org/obo/MONDO_0100096
T7 814-822 Disease denotes COVID-19 http://purl.obolibrary.org/obo/MONDO_0100096
T8 901-909 Disease denotes COVID-19 http://purl.obolibrary.org/obo/MONDO_0100096
T9 942-950 Disease denotes COVID-19 http://purl.obolibrary.org/obo/MONDO_0100096
T10 1019-1027 Disease denotes COVID-19 http://purl.obolibrary.org/obo/MONDO_0100096
T11 1028-1037 Disease denotes infection http://purl.obolibrary.org/obo/MONDO_0005550
T12 1176-1184 Disease denotes COVID-19 http://purl.obolibrary.org/obo/MONDO_0100096
T13 1263-1271 Disease denotes COVID-19 http://purl.obolibrary.org/obo/MONDO_0100096
T14 1365-1373 Disease denotes COVID-19 http://purl.obolibrary.org/obo/MONDO_0100096
T15 1416-1424 Disease denotes COVID-19 http://purl.obolibrary.org/obo/MONDO_0100096
T16 1660-1668 Disease denotes COVID-19 http://purl.obolibrary.org/obo/MONDO_0100096
T17 1779-1787 Disease denotes COVID-19 http://purl.obolibrary.org/obo/MONDO_0100096
T18 1988-1996 Disease denotes COVID-19 http://purl.obolibrary.org/obo/MONDO_0100096
T19 2082-2090 Disease denotes COVID-19 http://purl.obolibrary.org/obo/MONDO_0100096
T20 2238-2246 Disease denotes COVID-19 http://purl.obolibrary.org/obo/MONDO_0100096
T21 2316-2324 Disease denotes COVID-19 http://purl.obolibrary.org/obo/MONDO_0100096
T22 2346-2371 Disease denotes hypersensitivity reaction http://purl.obolibrary.org/obo/MONDO_0000605
T23 2346-2362 Disease denotes hypersensitivity http://purl.obolibrary.org/obo/MONDO_0005271
T24 2437-2452 Disease denotes retinal disease http://purl.obolibrary.org/obo/MONDO_0005283
T25 2462-2471 Disease denotes porphyria http://purl.obolibrary.org/obo/MONDO_0019142|http://purl.obolibrary.org/obo/MONDO_0037939
T27 2481-2503 Disease denotes chronic kidney disease http://purl.obolibrary.org/obo/MONDO_0005300
T28 2489-2503 Disease denotes kidney disease http://purl.obolibrary.org/obo/MONDO_0001343|http://purl.obolibrary.org/obo/MONDO_0005240
T30 2505-2508 Disease denotes CKD http://purl.obolibrary.org/obo/MONDO_0005300
T31 2534-2542 Disease denotes epilepsy http://purl.obolibrary.org/obo/MONDO_0005027
T32 2552-2565 Disease denotes heart failure http://purl.obolibrary.org/obo/MONDO_0005252
T33 2610-2623 Disease denotes liver disease http://purl.obolibrary.org/obo/MONDO_0005154
T34 2625-2643 Disease denotes Gilbert's syndrome http://purl.obolibrary.org/obo/MONDO_0007745
T35 2703-2707 Disease denotes G6PD http://purl.obolibrary.org/obo/MONDO_0005775
T36 5783-5791 Disease denotes COVID-19 http://purl.obolibrary.org/obo/MONDO_0100096

LitCovid-PD-CLO

Id Subject Object Predicate Lexical cue
T1 147-148 http://purl.obolibrary.org/obo/CLO_0001020 denotes A
T2 171-172 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T3 192-193 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T4 223-233 http://purl.obolibrary.org/obo/BFO_0000030 denotes OBJECTIVES
T5 243-252 http://purl.obolibrary.org/obo/BFO_0000030 denotes OBJECTIVE
T6 440-450 http://purl.obolibrary.org/obo/BFO_0000030 denotes OBJECTIVES
T7 689-692 http://www.ebi.ac.uk/efo/EFO_0001410 denotes arm
T8 718-723 http://purl.obolibrary.org/obo/UBERON_0000473 denotes tests
T9 749-756 http://purl.obolibrary.org/obo/UBERON_0000473 denotes testing
T10 857-864 http://purl.obolibrary.org/obo/UBERON_0000473 denotes testing
T11 924-927 http://www.ebi.ac.uk/efo/EFO_0001410 denotes arm
T12 982-985 http://www.ebi.ac.uk/efo/EFO_0001410 denotes arm
T13 1052-1055 http://www.ebi.ac.uk/efo/EFO_0001410 denotes arm
T14 1068-1078 http://purl.obolibrary.org/obo/BFO_0000030 denotes OBJECTIVES
T15 1194-1199 http://purl.obolibrary.org/obo/UBERON_0000473 denotes tests
T16 1324-1329 http://purl.obolibrary.org/obo/UBERON_0000178 denotes blood
T17 1324-1329 http://www.ebi.ac.uk/efo/EFO_0000296 denotes blood
T18 1441-1444 http://www.ebi.ac.uk/efo/EFO_0001410 denotes arm
T19 1489-1492 http://www.ebi.ac.uk/efo/EFO_0001410 denotes arm
T20 1719-1720 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T21 1924-1926 http://purl.obolibrary.org/obo/CLO_0050510 denotes 18
T22 2008-2009 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T23 2121-2127 http://purl.obolibrary.org/obo/UBERON_0001456 denotes facing
T24 2256-2260 http://purl.obolibrary.org/obo/UBERON_0000473 denotes test
T25 2489-2495 http://purl.obolibrary.org/obo/UBERON_0002113 denotes kidney
T26 2489-2495 http://www.ebi.ac.uk/efo/EFO_0000927 denotes kidney
T27 2489-2495 http://www.ebi.ac.uk/efo/EFO_0000929 denotes kidney
T28 2552-2557 http://purl.obolibrary.org/obo/UBERON_0000948 denotes heart
T29 2552-2557 http://purl.obolibrary.org/obo/UBERON_0007100 denotes heart
T30 2552-2557 http://purl.obolibrary.org/obo/UBERON_0015228 denotes heart
T31 2552-2557 http://www.ebi.ac.uk/efo/EFO_0000815 denotes heart
T32 2610-2615 http://purl.obolibrary.org/obo/UBERON_0002107 denotes liver
T33 2610-2615 http://www.ebi.ac.uk/efo/EFO_0000887 denotes liver
T34 2720-2722 http://purl.obolibrary.org/obo/CLO_0053733 denotes 11
T35 3003-3004 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T36 3170-3176 http://purl.obolibrary.org/obo/CLO_0001658 denotes active
T37 3354-3355 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T38 3369-3375 http://purl.obolibrary.org/obo/OBI_0000968 denotes device
T39 3551-3552 http://purl.obolibrary.org/obo/CLO_0001020 denotes A
T40 3582-3583 http://purl.obolibrary.org/obo/CLO_0001021 denotes B
T41 3864-3868 http://www.ebi.ac.uk/efo/EFO_0001410 denotes arms
T42 3970-3974 http://www.ebi.ac.uk/efo/EFO_0001410 denotes arms
T43 3989-3990 http://purl.obolibrary.org/obo/CLO_0001020 denotes A
T44 3992-3993 http://purl.obolibrary.org/obo/CLO_0001021 denotes B
T45 4037-4040 http://www.ebi.ac.uk/efo/EFO_0001410 denotes Arm
T46 4041-4042 http://purl.obolibrary.org/obo/CLO_0001020 denotes A
T47 4044-4050 http://purl.obolibrary.org/obo/CLO_0001658 denotes Active
T48 4190-4196 http://purl.obolibrary.org/obo/CLO_0001658 denotes Active
T49 4281-4282 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T50 4504-4505 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T51 4577-4580 http://www.ebi.ac.uk/efo/EFO_0001410 denotes Arm
T52 4581-4582 http://purl.obolibrary.org/obo/CLO_0001021 denotes B
T53 4584-4590 http://purl.obolibrary.org/obo/CLO_0001658 denotes Active
T54 4730-4736 http://purl.obolibrary.org/obo/CLO_0001658 denotes Active
T55 4911-4912 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T56 5106-5109 http://www.ebi.ac.uk/efo/EFO_0001410 denotes Arm
T57 5569-5570 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T58 5642-5643 http://purl.obolibrary.org/obo/CLO_0001020 denotes A
T59 5873-5877 http://purl.obolibrary.org/obo/UBERON_0000473 denotes test
T60 6085-6088 http://purl.obolibrary.org/obo/CLO_0001577 denotes a 3
T61 6479-6480 http://purl.obolibrary.org/obo/CLO_0001020 denotes A
T62 6747-6751 http://purl.obolibrary.org/obo/CLO_0001564 denotes a 20
T63 6747-6751 http://purl.obolibrary.org/obo/CLO_0050194 denotes a 20
T64 7595-7598 http://purl.obolibrary.org/obo/CLO_0051582 denotes has
T65 7638-7639 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T66 7709-7712 http://purl.obolibrary.org/obo/CLO_0051582 denotes has

LitCovid-PD-CHEBI

Id Subject Object Predicate Lexical cue chebi_id
T1 22-40 Chemical denotes hydroxychloroquine http://purl.obolibrary.org/obo/CHEBI_5801
T2 297-315 Chemical denotes hydroxychloroquine http://purl.obolibrary.org/obo/CHEBI_5801
T3 528-546 Chemical denotes hydroxychloroquine http://purl.obolibrary.org/obo/CHEBI_5801
T4 1146-1164 Chemical denotes hydroxychloroquine http://purl.obolibrary.org/obo/CHEBI_5801
T5 1330-1335 Chemical denotes group http://purl.obolibrary.org/obo/CHEBI_24433
T6 2375-2393 Chemical denotes hydroxychloroquine http://purl.obolibrary.org/obo/CHEBI_5801
T7 2395-2406 Chemical denotes chloroquine http://purl.obolibrary.org/obo/CHEBI_3638
T8 2412-2427 Chemical denotes aminoquinolines http://purl.obolibrary.org/obo/CHEBI_36709
T9 2437-2444 Chemical denotes retinal http://purl.obolibrary.org/obo/CHEBI_15035
T10 2668-2675 Chemical denotes glucose http://purl.obolibrary.org/obo/CHEBI_17234|http://purl.obolibrary.org/obo/CHEBI_4167
T12 2678-2687 Chemical denotes phosphate http://purl.obolibrary.org/obo/CHEBI_18367|http://purl.obolibrary.org/obo/CHEBI_26020|http://purl.obolibrary.org/obo/CHEBI_35780|http://purl.obolibrary.org/obo/CHEBI_43474
T16 2800-2811 Chemical denotes Chloroquine http://purl.obolibrary.org/obo/CHEBI_3638
T17 2813-2825 Chemical denotes Halofantrine http://purl.obolibrary.org/obo/CHEBI_5612
T18 2827-2837 Chemical denotes Amiodarone http://purl.obolibrary.org/obo/CHEBI_2663
T19 2839-2851 Chemical denotes Moxifloxacin http://purl.obolibrary.org/obo/CHEBI_63611
T20 2892-2905 Chemical denotes Ciprofloxacin http://purl.obolibrary.org/obo/CHEBI_100241
T21 2907-2921 Chemical denotes Clarithromycin http://purl.obolibrary.org/obo/CHEBI_3732
T22 2923-2939 Chemical denotes Prochlorperazine http://purl.obolibrary.org/obo/CHEBI_8435
T23 2974-2992 Chemical denotes hydroxychloroquine http://purl.obolibrary.org/obo/CHEBI_5801
T24 3036-3054 Chemical denotes hydroxychloroquine http://purl.obolibrary.org/obo/CHEBI_5801
T25 3560-3578 Chemical denotes hydroxychloroquine http://purl.obolibrary.org/obo/CHEBI_5801
T26 3592-3610 Chemical denotes hydroxychloroquine http://purl.obolibrary.org/obo/CHEBI_5801
T27 3907-3925 Chemical denotes hydroxychloroquine http://purl.obolibrary.org/obo/CHEBI_5801
T28 4106-4124 Chemical denotes hydroxychloroquine http://purl.obolibrary.org/obo/CHEBI_5801
T29 4197-4215 Chemical denotes hydroxychloroquine http://purl.obolibrary.org/obo/CHEBI_5801
T30 4427-4445 Chemical denotes hydroxychloroquine http://purl.obolibrary.org/obo/CHEBI_5801
T31 4647-4665 Chemical denotes hydroxychloroquine http://purl.obolibrary.org/obo/CHEBI_5801
T32 4737-4755 Chemical denotes hydroxychloroquine http://purl.obolibrary.org/obo/CHEBI_5801
T33 5000-5018 Chemical denotes hydroxychloroquine http://purl.obolibrary.org/obo/CHEBI_5801
T34 5184-5202 Chemical denotes hydroxychloroquine http://purl.obolibrary.org/obo/CHEBI_5801
T35 5274-5292 Chemical denotes hydroxychloroquine http://purl.obolibrary.org/obo/CHEBI_5801
T36 5476-5494 Chemical denotes hydroxychloroquine http://purl.obolibrary.org/obo/CHEBI_5801
T37 5936-5954 Chemical denotes hydroxychloroquine http://purl.obolibrary.org/obo/CHEBI_5801
T38 6100-6118 Chemical denotes hydroxychloroquine http://purl.obolibrary.org/obo/CHEBI_5801
T39 6128-6146 Chemical denotes hydroxychloroquine http://purl.obolibrary.org/obo/CHEBI_5801
T40 6865-6883 Chemical denotes hydroxychloroquine http://purl.obolibrary.org/obo/CHEBI_5801
T41 6891-6909 Chemical denotes hydroxychloroquine http://purl.obolibrary.org/obo/CHEBI_5801
T42 7621-7627 Chemical denotes Letter http://purl.obolibrary.org/obo/CHEBI_6446

LitCovid-PD-HP

Id Subject Object Predicate Lexical cue hp_id
T1 2346-2362 Phenotype denotes hypersensitivity http://purl.obolibrary.org/obo/HP_0041092
T2 2437-2452 Phenotype denotes retinal disease http://purl.obolibrary.org/obo/HP_0000479
T3 2481-2503 Phenotype denotes chronic kidney disease http://purl.obolibrary.org/obo/HP_0012622
T4 2534-2542 Phenotype denotes epilepsy http://purl.obolibrary.org/obo/HP_0001250
T5 2552-2565 Phenotype denotes heart failure http://purl.obolibrary.org/obo/HP_0001635
T6 2610-2623 Phenotype denotes liver disease http://purl.obolibrary.org/obo/HP_0001392

LitCovid-PD-GO-BP

Id Subject Object Predicate Lexical cue
T1 2346-2362 http://purl.obolibrary.org/obo/GO_0002524 denotes hypersensitivity
T2 2510-2514 http://purl.obolibrary.org/obo/GO_0005006 denotes eGFR

LitCovid-sentences

Id Subject Object Predicate Lexical cue
T1 0-146 Sentence denotes ChemoPROphyLaxIs with hydroxychloroquine For covId-19 infeCtious disease (PROLIFIC) to prevent covid-19 infection in frontline healthcare workers:
T2 147-222 Sentence denotes A structured summary of a study protocol for a randomised controlled trial.
T3 223-253 Sentence denotes OBJECTIVES: PRIMARY OBJECTIVE:
T4 254-429 Sentence denotes To determine whether chemoprophylaxis with hydroxychloroquine versus placebo increases time to contracting coronavirus disease 2019 (COVID-19) in frontline healthcare workers.
T5 430-451 Sentence denotes SECONDARY OBJECTIVES:
T6 452-626 Sentence denotes 1) To determine whether chemoprophylaxis with daily versus weekly dosing of hydroxychloroquine increases time to contracting COVID-19 disease in frontline healthcare workers.
T7 627-1079 Sentence denotes 2) To compare the number of COVID-19 cases between each trial arm on the basis of positive tests (as per current clinical testing methods and/or serology) 3) To compare the percentage of COVID-19 positive individuals with current testing methods versus serologically-proven COVID-19 in each trial arm 4) To compare COVID-19 disease severity in each trial arm 5) To compare recovery time from COVID-19 infection in each trial arm EXPLORATORY OBJECTIVES:
T8 1080-1458 Sentence denotes 1) To determine compliance (as measured by trough pharmacokinetic hydroxychloroquine levels) on COVID-19 positive tests 2) To determine if genetic factors determine susceptibility to COVID-19 disease or response to treatment 3) To determine if blood group determines susceptibility to COVID-19 disease 4) To compare serum biomarkers of COVID-19 disease in each arm TRIAL DESIGN:
T9 1459-1556 Sentence denotes Double-blind, multi-centre, 2-arm (3:3:2 ratio) randomised placebo-controlled trial PARTICIPANTS:
T10 1557-1669 Sentence denotes National Health Service (NHS) workers who have direct patient contact delivering care to patients with COVID-19.
T11 1670-1788 Sentence denotes Participants in the trial will be recruited from a number of NHS hospitals directly caring for patients with COVID-19.
T12 1789-1808 Sentence denotes INCLUSION CRITERIA:
T13 1809-1858 Sentence denotes To be included in the trial the participant MUST:
T14 1859-2152 Sentence denotes 1) Have given written informed consent to participate 2) Be aged 18 years to 70 years 3) Not previously have been diagnosed with COVID-19 4) Work in a high-risk secondary or tertiary healthcare setting (hospitals accepting COVID-19 patients) with direct patient-facing care EXCLUSION CRITERIA:
T15 2153-2228 Sentence denotes The presence of any of the following will mean participants are ineligible:
T16 2229-2790 Sentence denotes 1) Known COVID-19 positive test at baseline (if available) 2) Symptomatic for possible COVID-19 at baseline 3) Known hypersensitivity reaction to hydroxychloroquine, chloroquine or 4-aminoquinolines 4) Known retinal disease 5) Known porphyria 6) Known chronic kidney disease (CKD; eGFR<30ml/min) 7) Known epilepsy 8) Known heart failure or conduction problems 9) Known significant liver disease (Gilbert's syndrome is permitted) 10) Known glucose-6-phosphate dehydrogenase (G6PD) deficiency 11) Currently taking any of the following contraindicated medications:
T17 2791-3515 Sentence denotes Digoxin, Chloroquine, Halofantrine, Amiodarone, Moxifloxacin, Cyclosporin, Mefloquine, Praziquantel, Ciprofloxacin, Clarithromycin, Prochlorperazine, Fluconazole 12) Currently taking hydroxychloroquine or having a clinical indication for taking hydroxychloroquine 13) Currently breastfeeding 14) Unable to be followed-up during the trial 15) Current or future involvement in the active treatment phase of other interventional research studies (excluding observational/non-interventional studies) before study follow-up visit 16) Not able to use or have access to a modern phone device/web-based technology 17) Any other clinical reason which may preclude entry in the opinion of the investigator INTERVENTION AND COMPARATOR:
T18 3516-3696 Sentence denotes Interventions being evaluated are: A) Daily hydroxychloroquine or B) Weekly hydroxychloroquine or C) Placebo The maximum treatment period is approximately 13 weeks per participant.
T19 3697-3869 Sentence denotes Hydroxychloroquine-identical matched placebo tablets will ensure that all participants are taking the same number and dosing regimen of tablets across the three trial arms.
T20 3870-3936 Sentence denotes There is no variation in the dose of hydroxychloroquine by weight.
T21 3937-4036 Sentence denotes The dosing regimen for the three arms of the study (A, B, C) are described in further detail below.
T22 4037-4043 Sentence denotes Arm A:
T23 4044-4142 Sentence denotes Active Hydroxychloroquine (- daily dosing and placebo-matched hydroxychloroquine - weekly dosing).
T24 4143-4148 Sentence denotes Form:
T25 4149-4163 Sentence denotes Tablets Route:
T26 4164-4169 Sentence denotes Oral.
T27 4170-4189 Sentence denotes Dose and Frequency:
T28 4190-4216 Sentence denotes Active hydroxychloroquine:
T29 4217-4226 Sentence denotes Days 1-2:
T30 4227-4313 Sentence denotes Loading phase - 400mg (2 x 200mg tablets) taken twice a day for 2 days Days 3 onwards:
T31 4314-4446 Sentence denotes Maintenance Phase - 200mg (1 x 200mg tablet) taken once daily, every day for 90 days (~3 months) Matched Placebo hydroxychloroquine:
T32 4447-4462 Sentence denotes Days 3 onwards:
T33 4463-4583 Sentence denotes Maintenance Phase - 2 tablets taken once a week on the same day each week (every 7th day) for 90 days (~3 months) Arm B:
T34 4584-4688 Sentence denotes Active Hydroxychloroquine (- weekly dosing and placebo matched hydroxychloroquine - daily dosing.) Form:
T35 4689-4703 Sentence denotes Tablets Route:
T36 4704-4709 Sentence denotes Oral.
T37 4710-4729 Sentence denotes Dose and Frequency:
T38 4730-4756 Sentence denotes Active hydroxychloroquine:
T39 4757-4766 Sentence denotes Days 1-2:
T40 4767-4853 Sentence denotes Loading Phase - 400mg (2 x 200mg tablets) taken twice daily for 2 days Days 3 onwards:
T41 4854-5019 Sentence denotes Maintenance Phase - 400mg (2 x 200mg tablets) taken once a week on the same day each week (every 7th day) for 90 days (~3 months) Matched Placebo hydroxychloroquine:
T42 5020-5035 Sentence denotes Days 3 onwards:
T43 5036-5112 Sentence denotes Maintenance Phase - 1 tablet taken once daily for 90 days (~3 months) Arm C:
T44 5113-5226 Sentence denotes Matched placebo Hydroxychloroquine (- daily dosing and matched placebo hydroxychloroquine - weekly dosing.) Form:
T45 5227-5233 Sentence denotes Table.
T46 5234-5240 Sentence denotes Route:
T47 5241-5246 Sentence denotes Oral.
T48 5247-5257 Sentence denotes Frequency:
T49 5258-5308 Sentence denotes Matched placebo hydroxychloroquine - daily dosing:
T50 5309-5318 Sentence denotes Days 1-2:
T51 5319-5389 Sentence denotes Loading Phase - 2 tablets taken twice daily for 2 days Days 3 onwards:
T52 5390-5511 Sentence denotes Maintenance Phase - 1 tablet taken once daily for 90 days (~3 months) Matched placebo hydroxychloroquine - weekly dosing:
T53 5512-5527 Sentence denotes Days 3 onwards:
T54 5528-5737 Sentence denotes Maintenance Phase - 2 tablets taken once a week on the same day each week (every 7th day) for 90 days (~3 months) A schematic of the dosing schedule can be found in the full study protocol (Additional File 1).
T55 5738-5752 Sentence denotes MAIN OUTCOMES:
T56 5753-5893 Sentence denotes Time to diagnosis of positive COVID-19 disease (defined by record of date of symptoms onset and confirmed by laboratory test) RANDOMISATION:
T57 5894-6059 Sentence denotes Participants will be randomised to either hydroxychloroquine dosed daily with weekly placebo, HCQ dosed weekly with daily placebo, or placebo dosed daily and weekly.
T58 6060-6204 Sentence denotes Randomisation will be in a 3:3:2 ratio [hydroxychloroquine-(daily), hydroxychloroquine-(weekly), placebo], using stratified block randomisation.
T59 6205-6279 Sentence denotes Random block sizes will be used, and stratification will be by study site.
T60 6280-6299 Sentence denotes BLINDING (MASKING):
T61 6300-6438 Sentence denotes Participants and trial investigators consenting participants, delivering trial assessments and procedures will be blinded to intervention.
T62 6439-6478 Sentence denotes NUMBERS TO BE RANDOMISED (SAMPLE SIZE):
T63 6479-6642 Sentence denotes A sufficient number of participants will be enrolled so that approximately 1000 participants in total will have data suitable for the primary statistical analysis.
T64 6643-6790 Sentence denotes It is anticipated that approximately 1,200 participants will need to be enrolled in total, to allow for a 20% dropout over the period of the trial.
T65 6791-6975 Sentence denotes This would result in approximately 450:450:300 participants randomised to hydroxychloroquine daily, hydroxychloroquine weekly+daily matched placebo or matched-placebo daily and weekly.
T66 6976-6989 Sentence denotes TRIAL STATUS:
T67 6990-7055 Sentence denotes V 1.0, 7th April 2020 EU Clinical Trials Register EudraCT Number:
T68 7056-7092 Sentence denotes 2020-001331-26 Date of registration:
T69 7093-7161 Sentence denotes 14th April 2020 Trial registered before first participant enrolment.
T70 7162-7228 Sentence denotes Trial site is Cambridge University Hospitals NHS Foundation Trust.
T71 7229-7266 Sentence denotes Recruitment started on 11th May 2020.
T72 7267-7323 Sentence denotes It is anticipated that the trial will run for 12 months.
T73 7324-7384 Sentence denotes The recruitment end date cannot yet be accurately predicted.
T74 7385-7399 Sentence denotes FULL PROTOCOL:
T75 7400-7508 Sentence denotes The full protocol is attached as an additional file, accessible from the Trials website (Additional file 1).
T76 7509-7689 Sentence denotes In the interest of expediting dissemination of this material, the familiar formatting has been eliminated; this Letter serves as a summary of the key elements of the full protocol.
T77 7690-7774 Sentence denotes The study protocol has been reported in accordance with the Standard Protocol Items:
T78 7775-7866 Sentence denotes Recommendations for Clinical Interventional Trials (SPIRIT) guidelines (Additional file 2).

hydroxychloroquine

Id Subject Object Predicate Lexical cue hp_id
T1 2346-2362 Phenotype denotes hypersensitivity http://purl.obolibrary.org/obo/HP_0041092
T2 2437-2452 Phenotype denotes retinal disease http://purl.obolibrary.org/obo/HP_0000479
T3 2481-2503 Phenotype denotes chronic kidney disease http://purl.obolibrary.org/obo/HP_0012622
T4 2534-2542 Phenotype denotes epilepsy http://purl.obolibrary.org/obo/HP_0001250
T5 2552-2565 Phenotype denotes heart failure http://purl.obolibrary.org/obo/HP_0001635
T6 2610-2623 Phenotype denotes liver disease http://purl.obolibrary.org/obo/HP_0001392